Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer

Current Treatment Options in Oncology

Volumn 12, Issue 4, 2011, Pages 403-411

  Abramson, Vandana G ^a   Mayer, Ingrid A ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CA 27.79 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUCIN 1; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG RESPONSE; EARLY CANCER; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84855892405     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0164-2     Document Type: Article

References (36)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-36.
2. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer. 2005;5:591-602. (Pubitemid 41081385)
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-26. (Pubitemid 40051905)
4. Straver ME, Glas AM, Hannemann J, et al. The 70- gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551-8.
5. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431-57. (Pubitemid 351738187)
6. Kufe DW. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer. 2009;9:874-85.
7. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol. 1998;19 Suppl 1:1-20. (Pubitemid 128707598)
8. Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997;15:2322-8. (Pubitemid 27251134)
9. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol. 2003;30:338-48. (Pubitemid 36706558)
10. Nicolini A, Tartarelli G, Carpi A, et al. Intensive postoperative follow-up of breast cancer patients with tumourmarkers: CEA, TPA or CA15.3 vsMCA andMCACA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269.
11. Valenzuela P, Mateos S, Tello E, Lopez-Bueno MJ, Garrido N, Gaspar MJ. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol. 2003;24:60-2. (Pubitemid 36268189)
12. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res. 2001;7:2357-62. (Pubitemid 32751636)
13. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41-8.
14. Jager W, Kramer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl. 1995;221:87-92.
15. Molina R, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem. 2010;56:1148-57.
16. Kokko R, Holli K, Hakama M. Ca 15-3 in the followup of localised breast cancer: A prospective study. Eur J Cancer. 2002;38:1189-93. (Pubitemid 34603478)
17. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312. (Pubitemid 350232263)
18. Cheung KL, Evans AJ, Robertson JF. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat. 2001;67:273-8. (Pubitemid 32803533)
19. Kurebayashi J, Nishimura R, Tanaka K, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study. Breast Cancer. 2004;11:389-95.
20. Tampellini M, Berruti A, Bitossi R, et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006;98:241-8. (Pubitemid 44195593)
21. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat. 1998;52:239-59. (Pubitemid 29056099)
22. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990;65:193-9. (Pubitemid 20035340)
23. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5:1950-60. (Pubitemid 29399243)
24. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the Cell Search system. Clin Cancer Res. 2007;13:920-8. (Pubitemid 46340368)
25. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-91. (Pubitemid 39095313)
26. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218-24.
27. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420-30.
28. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system? Cancer. 2008;113:2422-30.
29. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13:R67.
30. Bidard F, Hajage D, Bachelot T, Andre F, Brain EG, Campone M, Dieras V, Asselain B, Mathiot C, Pierga J. Circulating tumor cells and Cyfra 21-1 as outcomeassociated biomarkers In First Line Metastatic Breast Cancer: Results Of The Ic 2006-04 Study. Ann Oncol. 2011;22. This is the first prospective study of patients with metastatic breast cancer with CTC-associated outcome as the primary endpoint; CTC counts were correlated with overall survival.
31. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, et al. Use of Circulating Tumor Cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. JClinOncol. 2010;28. This is the largest study examining the prognostic value of CTCs before and after adjuvant chemotherapy in early stage breast cancer.
32. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, et al. Use of Circulating Tumor Cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol. 2010;28.
33. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004-10.
34. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634-45.
35. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403-9. (Pubitemid 44799711)
36. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303-11. This study correlates CTCs with imaging by PET/CT and shows CTCs to be better predictors of overall survival than PET/CT.